NEW YORK, July 5, 2017 /PRNewswire/ --
If you want a Stock Review on BMY, LLY, AZN or SNY then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. DailyStockTracker.com presents for evaluation these Major Drug Manufacturers equities: Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), AstraZeneca PLC (NYSE: AZN), and Sanofi (NYSE:
Bristol Myers Squibb
New York headquartered Bristol-Myers Squibb Co.'s stock rose 0.99%, finishing Monday's trading session at $56.27. A total volume of 6.26 million shares was traded. The Company's shares have gained 2.36% in the last month and 3.80% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.85% and 2.89%, respectively. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 58.30.
On June 16th, 2017, Bristol-Myers Squibb and SK Biotek Co., Ltd announced that they have signed a definitive purchase agreement to sell the former's small molecule active pharmaceutical ingredient manufacturing facility in Swords, Ireland, to SK Biotek, a wholly owned subsidiary of SK Holdings, based in Seoul, South Korea. The companies intend to complete the deal by the fourth quarter 2017, at which time SK Biotek will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site. See our free and comprehensive research report on BMY at:
Shares in Indiana headquartered Eli Lilly and Co. ended at $82.70, up 0.49% from the last trading session. The stock recorded a trading volume of 1.46 million shares. The Company's shares have advanced 3.21% in the past month and 12.44% since the start of this year. The stock is trading 2.28% and 4.96% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 53.72.
On June 19th, 2017, Eli Lilly's Board of Directors has declared a dividend for Q3 2017 of $0.52 per share on outstanding common stock. The dividend is payable on September 08th, 2017, to shareholders of record at the close of business on August 15th, 2017. LLY free research report is just a click away at:
On Monday, shares in the UK headquartered AstraZeneca PLC recorded a trading volume of 1.70 million shares. The stock declined 0.62%, closing the day at $33.88. The Company's shares have gained 8.80% over the previous three months and 24.01% on an YTD basis. The stock is trading 1.83% above its 50-day moving average and 11.93% above its 200-day moving average. Additionally, shares of AstraZeneca, which engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 47.86.
On June 06th, 2017, AstraZeneca reported further evidence that Tagrisso® (osimertinib), the potential new standard of care for patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, also shows clinical activity in those patients with disease progression to central nervous system metastases. The data, presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, are consistent with earlier clinical and preclinical findings, showing the potential of osimertinib to penetrate the blood-brain barrier. Sign up for your complimentary report on AZN at:
At the close of trading on Monday, shares in France headquartered Sanofi recorded a trading volume of 359,232 shares. The stock finished the session 0.23% lower at $47.80. The Company's shares have gained 5.89% in the previous three months and 18.20% since the start of this year. The stock is trading above its 200-day moving average by 11.36%. Furthermore, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have an RSI of 41.25.
On June 27th, 2017, Sanofi and its specialty care global business unit, Sanofi Genzyme, announced that the European Commission has granted marketing authorization for Kevzara® (sarilumab) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs. Sarilumab may be used as monotherapy in case of intolerance to MTX, or when treatment with methotrexate is inappropriate. Register for free on DailyStockTracker.com and download the latest research report on SNY at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All